Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.19
ANGO's Cash to Debt is ranked lower than
85% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. ANGO: 0.19 )
Ranked among companies with meaningful Cash to Debt only.
ANGO' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 6.67 Max: N/A
Current: 0.19
Equity to Asset 0.73
ANGO's Equity to Asset is ranked higher than
67% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. ANGO: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
ANGO' s Equity to Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.85 Max: 0.94
Current: 0.73
0.06
0.94
Interest Coverage 1.91
ANGO's Interest Coverage is ranked lower than
93% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.76 vs. ANGO: 1.91 )
Ranked among companies with meaningful Interest Coverage only.
ANGO' s Interest Coverage Range Over the Past 10 Years
Min: 1.35  Med: 22.03 Max: 74.68
Current: 1.91
1.35
74.68
F-Score: 5
Z-Score: 1.93
M-Score: -2.74
WACC vs ROIC
6.66%
1.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.83
ANGO's Operating margin (%) is ranked lower than
57% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. ANGO: 1.83 )
Ranked among companies with meaningful Operating margin (%) only.
ANGO' s Operating margin (%) Range Over the Past 10 Years
Min: -10  Med: 4.67 Max: 13.14
Current: 1.83
-10
13.14
Net-margin (%) -0.37
ANGO's Net-margin (%) is ranked lower than
61% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. ANGO: -0.37 )
Ranked among companies with meaningful Net-margin (%) only.
ANGO' s Net-margin (%) Range Over the Past 10 Years
Min: -8.13  Med: 2.32 Max: 8.75
Current: -0.37
-8.13
8.75
ROE (%) -0.24
ANGO's ROE (%) is ranked lower than
62% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. ANGO: -0.24 )
Ranked among companies with meaningful ROE (%) only.
ANGO' s ROE (%) Range Over the Past 10 Years
Min: -3.97  Med: 1.31 Max: 7.96
Current: -0.24
-3.97
7.96
ROA (%) -0.17
ANGO's ROA (%) is ranked lower than
59% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. ANGO: -0.17 )
Ranked among companies with meaningful ROA (%) only.
ANGO' s ROA (%) Range Over the Past 10 Years
Min: -3.51  Med: 1.14 Max: 6.98
Current: -0.17
-3.51
6.98
ROC (Joel Greenblatt) (%) 1.98
ANGO's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.53 vs. ANGO: 1.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANGO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -16.13  Med: 12.37 Max: 40.03
Current: 1.98
-16.13
40.03
Revenue Growth (3Y)(%) 4.60
ANGO's Revenue Growth (3Y)(%) is ranked lower than
53% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.10 vs. ANGO: 4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANGO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.2  Med: 8.75 Max: 25.2
Current: 4.6
3.2
25.2
EBITDA Growth (3Y)(%) 30.20
ANGO's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. ANGO: 30.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANGO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.1  Med: 6.20 Max: 31.9
Current: 30.2
-34.1
31.9
EPS Growth (3Y)(%) -22.90
ANGO's EPS Growth (3Y)(%) is ranked lower than
79% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. ANGO: -22.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANGO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.4  Med: -1.05 Max: 100
Current: -22.9
-35.4
100
» ANGO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ANGO Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Chuck Royce 505,703 sh (-0.90%)
Mario Gabelli 80,000 sh (-3.61%)
Jim Simons 216,600 sh (-17.91%)
» More
Q3 2015

ANGO Guru Trades in Q3 2015

Paul Tudor Jones 11,739 sh (New)
Jim Simons 256,851 sh (+18.58%)
Chuck Royce 538,703 sh (+6.53%)
Mario Gabelli 78,000 sh (-2.50%)
» More
Q4 2015

ANGO Guru Trades in Q4 2015

Jim Simons 364,400 sh (+41.87%)
Chuck Royce 640,801 sh (+18.95%)
Mario Gabelli 74,000 sh (-5.13%)
Paul Tudor Jones 10,139 sh (-13.63%)
» More
Q1 2016

ANGO Guru Trades in Q1 2016

Jim Simons 438,500 sh (+20.33%)
Chuck Royce 720,801 sh (+12.48%)
Paul Tudor Jones Sold Out
Mario Gabelli 66,000 sh (-10.81%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:LSE:AMS, TSE:7730, XKRX:041830, NAS:ATRC, MIL:SFL, ASX:NAN » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.

AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures & sells medical, surgical & diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease & for use in oncology & surgical settings. Its product offerings fall within three product groupings: Peripheral Vascular, Vascular Access & Oncology/Surgery. The Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. Fluid Management product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers & interventional accessories. These devices are utilized together & allow clinicians to aspirate or inject contrast, saline, remove waste & monitor invasive blood pressures throughout the procedure. Venous products focus on the treatment of varicose veins & consist of its VenaCure EVLT laser system & Sotradecol. VenaCure EVLT laser system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Sotradecol (sodium tetradecyl sulfate injection) is an FDA approved sclerosing drug that it distribute through a agreement with the manufacturer. Thrombus Management product offerings includes AngioVac & thrombolytic products. In fiscal 2013, the Company released its AngioVac venous drainage system which includes a Venous Drainage Cannula & Cardiopulmonary Bypass Circuit. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, & reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins & surgical bypass grafts. The Company's other core peripheral vascular products include Angiographic products & accessories, drainage, micro access & other products. Angiographic products & accessories are used during peripheral vascular interventional procedures. Drainage products percutaneously drain abscesses & other fluid pockets. An abscess is a tender inflamed mass that typically must be drained by a physician. Image-guided vascular access, or IGVA, involves the use of imaging equipment to guide the placement of catheters that deliver short-term drug therapies, such as chemotherapeutic agents & antibiotics, into the central venous system. The BioFlo products incorporate Endexo Technology into the manufacturing & design of its Vascular Access products. A peripherally inserted central catheter, or PICC, is a long thin catheter that is inserted into a peripheral vein, typically in the upper arm, & until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access. Ports are implantable devices utilized

Ratios

vs
industry
vs
history
Forward P/E 18.69
ANGO's Forward P/E is ranked higher than
67% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.96 vs. ANGO: 18.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 17.17
ANGO's Price/Owner Earnings (ttm) is ranked higher than
75% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.85 vs. ANGO: 17.17 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ANGO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.11  Med: 24.07 Max: 4173.33
Current: 17.17
10.11
4173.33
P/B 0.83
ANGO's P/B is ranked higher than
91% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. ANGO: 0.83 )
Ranked among companies with meaningful P/B only.
ANGO' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 0.97 Max: 6.71
Current: 0.83
0.64
6.71
P/S 1.23
ANGO's P/S is ranked higher than
71% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. ANGO: 1.23 )
Ranked among companies with meaningful P/S only.
ANGO' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.70 Max: 5.51
Current: 1.23
1.02
5.51
PFCF 12.78
ANGO's PFCF is ranked higher than
87% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.49 vs. ANGO: 12.78 )
Ranked among companies with meaningful PFCF only.
ANGO' s PFCF Range Over the Past 10 Years
Min: 8.78  Med: 31.08 Max: 837.6
Current: 12.78
8.78
837.6
POCF 11.69
ANGO's POCF is ranked higher than
72% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.58 vs. ANGO: 11.69 )
Ranked among companies with meaningful POCF only.
ANGO' s POCF Range Over the Past 10 Years
Min: 8.4  Med: 17.55 Max: 252.67
Current: 11.69
8.4
252.67
EV-to-EBIT 202.05
ANGO's EV-to-EBIT is ranked lower than
98% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.36 vs. ANGO: 202.05 )
Ranked among companies with meaningful EV-to-EBIT only.
ANGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -306.4  Med: 17.25 Max: 2726.8
Current: 202.05
-306.4
2726.8
EV-to-EBITDA 17.13
ANGO's EV-to-EBITDA is ranked lower than
51% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.91 vs. ANGO: 17.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -874.8  Med: 15.25 Max: 171.6
Current: 17.13
-874.8
171.6
Shiller P/E 99.41
ANGO's Shiller P/E is ranked lower than
92% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 37.39 vs. ANGO: 99.41 )
Ranked among companies with meaningful Shiller P/E only.
ANGO' s Shiller P/E Range Over the Past 10 Years
Min: 43.6  Med: 81.43 Max: 106
Current: 99.41
43.6
106
Current Ratio 2.43
ANGO's Current Ratio is ranked lower than
54% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. ANGO: 2.43 )
Ranked among companies with meaningful Current Ratio only.
ANGO' s Current Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.18 Max: 14.28
Current: 2.43
1.95
14.28
Quick Ratio 1.36
ANGO's Quick Ratio is ranked lower than
60% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. ANGO: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
ANGO' s Quick Ratio Range Over the Past 10 Years
Min: 1.16  Med: 3.97 Max: 12.12
Current: 1.36
1.16
12.12
Days Inventory 146.29
ANGO's Days Inventory is ranked lower than
60% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.83 vs. ANGO: 146.29 )
Ranked among companies with meaningful Days Inventory only.
ANGO' s Days Inventory Range Over the Past 10 Years
Min: 116.22  Med: 140.45 Max: 174.24
Current: 146.29
116.22
174.24
Days Sales Outstanding 56.58
ANGO's Days Sales Outstanding is ranked higher than
63% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.25 vs. ANGO: 56.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.92  Med: 59.07 Max: 79.96
Current: 56.58
45.92
79.96
Days Payable 38.08
ANGO's Days Payable is ranked lower than
65% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.30 vs. ANGO: 38.08 )
Ranked among companies with meaningful Days Payable only.
ANGO' s Days Payable Range Over the Past 10 Years
Min: 46.17  Med: 55.91 Max: 111.22
Current: 38.08
46.17
111.22

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.59
ANGO's Price/Tangible Book is ranked lower than
95% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.63 vs. ANGO: 20.59 )
Ranked among companies with meaningful Price/Tangible Book only.
ANGO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.58  Med: 3.18 Max: 297.22
Current: 20.59
1.58
297.22
Price/Projected FCF 0.70
ANGO's Price/Projected FCF is ranked higher than
93% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. ANGO: 0.70 )
Ranked among companies with meaningful Price/Projected FCF only.
ANGO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 0.86 Max: 1.09
Current: 0.7
0.53
1.09
Price/Median PS Value 0.73
ANGO's Price/Median PS Value is ranked higher than
80% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. ANGO: 0.73 )
Ranked among companies with meaningful Price/Median PS Value only.
ANGO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.02 Max: 3.08
Current: 0.73
0.65
3.08
Earnings Yield (Greenblatt) (%) 0.50
ANGO's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. ANGO: 0.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANGO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 4.70 Max: 12.3
Current: 0.5
0.4
12.3
Forward Rate of Return (Yacktman) (%) 7.39
ANGO's Forward Rate of Return (Yacktman) (%) is ranked lower than
58% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.42 vs. ANGO: 7.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANGO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.5  Med: 1.20 Max: 8.1
Current: 7.39
-15.5
8.1

More Statistics

Revenue (TTM) (Mil) $351.2
EPS (TTM) $ -0.03
Beta0.89
Short Percentage of Float3.71%
52-Week Range $9.71 - 17.00
Shares Outstanding (Mil)36.37

Analyst Estimate

May16 May17
Revenue (Mil $) 349 357
EPS ($) 0.56 0.65
EPS without NRI ($) 0.56 0.65
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : May 18, 2016 May 18 2016
PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell Apr 28 2016
PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell Apr 28 2016
AngioDynamics releases details of ex-CEO's severance package Apr 28 2016
ANGIODYNAMICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 27 2016
2 more executives leave one of Albany's biggest public companies Apr 21 2016
New AngioDynamics CEO: I'll focus on current business now, M&A next phase Apr 21 2016
ANGIODYNAMICS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 20 2016
ETF’s with exposure to AngioDynamics, Inc. : April 14, 2016 Apr 14 2016
ANGIODYNAMICS INC Financials Apr 13 2016
AngioDynamics, Inc. :ANGO-US: Earnings Analysis: Q3, 2016 By the Numbers Apr 13 2016
AngioDynamics, Inc. – Value Analysis (NASDAQ:ANGO) : April 12, 2016 Apr 12 2016
ANGIODYNAMICS INC Files SEC form 10-Q, Quarterly Report Apr 11 2016
AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : April 11,... Apr 11 2016
AngioDynamics Tops Q3 Earnings, Sales; FY16 View Pruned Apr 08 2016
ANGIODYNAMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 08 2016
Edited Transcript of ANGO earnings conference call or presentation 7-Apr-16 8:30pm GMT Apr 08 2016
AngioDynamics Inc Earnings Call scheduled for 4:30 pm ET today Apr 07 2016
AngioDynamics Reports Fiscal 2016 Third Quarter Results Apr 07 2016
AngioDynamics tops Street 3Q forecasts Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)